Article

From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9

2019-07-09

Abstract excerpt

Proprotein convertase substilisin-like/kexin type 9 (PCSK9) is a serine protease involved in a protein-protein interaction with the low-density lipoprotein (LDL) receptor that has both human genetic and clinical validation. Our pursuit of small molecule direct binders for this difficult to drug PPI target utilized affinity selection / mass spectrometry (AS/MS) which identified one confirmed hit compound. An x-ray...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8ec15a27-a909-5bdd-8d6b-efb21c533fed
DOI: 10.26434/chemrxiv.8800085.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9DOI 10.26434/chemrxiv.8800085.v1Read

Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.Semantic proximity Read

Potent Efficacy of Computer-Aided Designed Peptide Degrader Drug on PCSK9-Mediated HypercholesterolemiaSemantic proximity Read

The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.Semantic proximity Read

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.Semantic proximity Read

PCSK9: From discovery to therapeutic applications.Semantic proximity Read

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read

PCSK9 and LDL cholesterol: unravelling the target to design the bullet.Semantic proximity Read

PCSK9 inhibitors: the next frontier in low-density lipoprotein lowering.Semantic proximity Read

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity Read

The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.Semantic proximity Read

The contribution of native protein complexes to targeted protein degradationSemantic proximity Read

Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.Semantic proximity Read